Pharmacological venous thromboembolism prophylaxis in radical prostatectomy

被引:0
|
作者
Valverde-Martinez, Sebastian [1 ,2 ]
Gonzalez-Rayo, Laura-Andrea [3 ]
Padilla-Fernandez, Barbara [4 ]
Pereira-Bruno, Jorge [5 ]
Coelho, Hugo [6 ]
Montesino-Semper, Manuel [7 ]
Muller-Arteaga, Carlos [8 ]
Alvarez-Ossorio-Fernandez, Jose-Luis [9 ]
Migliorini, Filippo [10 ]
Garcia-Cenador, Maria-Begona [11 ]
Lorenzo-Gomez, Maria-Fernanda [1 ,11 ,12 ]
机构
[1] Inst Invest Biomed Salamanca IBSAL, Grp Invest Multidisciplinar Urol Renal GRUMUR, Salamanca, Spain
[2] Complejo Asistencial Univ Avila, Serv Urol, Avila, Spain
[3] Univ Rosario, Escuela Med & Ciencias Salud, Bogota, Colombia
[4] Hosp Univ Canarias, Serv Urol, Santa Cruz De Tenerife, Spain
[5] Hosp Univ Pero Covilha, Serv Urol, Covilha, Portugal
[6] Ctr Hosp & Univ Coimbra, Serv Urol, Coimbra, Portugal
[7] Hosp Univ Virgen del Camino, Serv Urol, Pamplona, Spain
[8] Complejo Univ Hosp Ourense, Serv Urol, Orense, Spain
[9] Hosp Univ Puerta dle Mar, Serv Urol, Cadiz, Spain
[10] Hosp Azienda Osped Univ Integrata, Serv Urol, Verona, Italy
[11] Univ Salamanca, Dept Cirugia, Salamanca, Spain
[12] Hosp Univ Salamanca, Serv Urol, Salamanca, Spain
来源
MEDICINA CLINICA | 2020年 / 154卷 / 04期
关键词
Radical prostatectomy; Thromboembolic prophylaxis; Clinical variability; CANCER-SURGERY; THROMBOPROPHYLAXIS; THROMBOSIS; UK;
D O I
10.1016/j.medcli.2019.04.023
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and aim: Pulmonary thromboembolism is one of the most common causes of non-surgical death in patients following urological abdominopelvic surgery. Since the beginning of prophylaxis for venous thromboembolic disease, episodes of deep vein thrombosis and pulmonary thromboembolism have decreased. Our objective is to analyse the prognosis factors of thromboembolic disease, the clinical variability in the use of pharmacological prophylaxis and the results of its application. Material and methods: Retrospective multicentric study of 610 patients undergoing radical prostatectomy between December 2013 and November 2014, in 7 general hospitals in Spain, Italy and Portugal. Patients were classified according to their baseline characteristics into thrombotic risk groups and haemorrhagic risk groups. The venous thromboembolic events that occurred in the different groups were analysed. Results: The average age was 65.22 years (48-78). The average body mass index was 26.7 and the average ASA risk 2.1. In all patients, early mobilization began in the first 24 hours. In 4.1% intermittent pneumatic compression was used and 84.6% received pharmacological prophylaxis with low molecular weight heparins. Only 3.4% used the combination of mechanical prophylaxis with pharmacological prophylaxis. We observed a decrease in the incidence of thromboembolic events in the patients who received pharmacological prophylaxis, with an absolute risk reduction of 6.8%. There was no increase in the risk of haemorrhage in the patients who received pharmacological prophylaxis. Conclusions: In this study on patients undergoing radical prostatectomy, there was no difference in haemorrhagic complications derived from the use of pharmacological prophylaxis for venous thromboembolic disease. Pharmacological prophylaxis reduces the risk of presenting a thromboembolic event in patients undergoing radical prostatectomy, although this risk is not associated with the approach technique. (C) 2019 Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码:113 / 118
页数:6
相关论文
共 50 条
  • [21] Rethinking pharmacological venous thromboembolism prophylaxis in minimally invasive gynaecological procedures
    Johns, Esther M. C.
    Ades, Alex
    Nanayakkara, Pavitra
    MEDICAL JOURNAL OF AUSTRALIA, 2021, 214 (02) : 60 - +
  • [22] Clinical Experience With Pharmacological Venous Thromboembolism Prophylaxis in the Underweight and Critically III
    Carter, Christopher
    Bushwitz, Jennifer
    Gowan, Mollie
    Pope, Hannah
    Human, Theresa
    Gibson, Gabrielle
    Owen, Emily
    Hampton, Nick
    Whitman, Craig
    ANNALS OF PHARMACOTHERAPY, 2016, 50 (10) : 832 - 839
  • [23] Pharmacological Prophylaxis of Venous Thromboembolism in Terminally Ill Patients: A Need or Futility?
    Serranito, Laura
    Reis-pina, Paulo
    ACTA MEDICA PORTUGUESA, 2022, 35 (02) : 147 - 149
  • [24] The necessity of pharmacological prophylaxis against venous thromboembolism in major joint arthroplasty
    Yassin, Mohamed
    Mitchell, Chris
    Diab, Mohammed
    Senior, Colin
    INTERNATIONAL ORTHOPAEDICS, 2014, 38 (05) : 1073 - 1075
  • [25] Patient Perspectives on Pharmacological Venous Thromboembolism Prophylaxis at The Johns Hopkins Hospital
    Wong, Adrian
    Streiff, Michael B.
    Haut, Elliott R.
    Kraus, Peggy S.
    Lau, Brandyn D.
    Brown, Victoria T.
    Efird, Leigh E.
    Hobson, Deborah B.
    Tandon, Sangeeta
    Pinto, Brian L.
    Rand, Cynthia S.
    Shermock, Kenneth M.
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2013, 35 (03) : 416 - 416
  • [26] PROPHYLAXIS OF VENOUS THROMBOEMBOLISM
    HIRSH, J
    MODERN CONCEPTS OF CARDIOVASCULAR DISEASE, 1984, 53 (05) : 25 - 29
  • [27] PROPHYLAXIS OF VENOUS THROMBOEMBOLISM
    KAKKAR, VV
    PROCEEDINGS OF THE ROYAL SOCIETY OF MEDICINE-LONDON, 1975, 68 (04): : 263 - 264
  • [28] PROPHYLAXIS FOR VENOUS THROMBOEMBOLISM
    BERGMANN, JF
    SEGRESTAA, JM
    CAULIN, C
    BMJ-BRITISH MEDICAL JOURNAL, 1992, 305 (6862): : 1156 - 1156
  • [29] Venous Thromboembolism Prophylaxis
    Hecht, Todd E. H.
    ANNALS OF INTERNAL MEDICINE, 2012, 156 (04) : 324 - 324
  • [30] Prophylaxis of venous thromboembolism
    Pineo, GF
    Hull, RD
    VENOUS THROMBOEMBOLISM: PREVENTION AND TREATMENT, 2005, : 158 - 182